Galectin Therapeutics Inc.

GALT · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analyst

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders53.1%

Institutions15.6%

Public / Other

Income Statement

	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$42.43M	-$38.07M	-$38.35M	-$30.18M	-$23.44M	-$13.44M	-$13.60M	-$16.25M	-$21.48M	-$20.08M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$47.05M	-$41.07M	-$38.78M	-$30.53M	-$23.46M	-$13.29M	-$13.90M	-$16.23M	-$21.44M	-$21.12M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$-0.52	$-0.41	$0.00	$0.00	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	$0.00	$-0.52	–	–	–	–	–	–

Balance Sheet

	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$15.12M	$25.66M	$18.59M	$39.65M	$27.14M	$47.48M	$8.25M	$3.05M	$15.36M	$25.85M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$17.50M	$28.20M	$21.29M	$41.83M	–	$48.47M	$9.01M	$4.16M	$15.79M	$26.41M
Everything the company owes — debt, unpaid bills, and other obligations.	$120.56M	$88.44M	$53.48M	$39.21M	–	$2.87M	$2.11M	$2.97M	$3.78M	$1.36M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$104.79M	-$61.96M	-$33.92M	$893000	–	$43.87M	$5.17M	-$530000	$10.29M	$18.04M

Cash Flow Statement

	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$41.80M	-$32.97M	-$31.06M	-$24.31M	-$20.60M	-$10.85M	-$10.18M	-$15.89M	-$16.41M	-$16.98M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	–	–	–	–	–	–	$0
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	–	–	–	–	–	–	-$16.98M

	You	Peer avg
Revenue Growth	–	+1003.9%
ROE	–	-182.1%

Galectin Therapeutics Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison